RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Motsch, Johann; Murta de Oliveira, Cláudia; Stus, Viktor; Köksal, Iftihar; Lyulko, Olexiy; W Boucher, Helen; S Kaye, Keith; M File, Thomas; L Brown, Michelle; Khan, Ireen; Du, Jiejun; Joeng, Hee-Koung; W Tipping, Robert; Aggrey, Angela; Young, Katherine; A Kartsonis, Nicholas; R Butterton, Joan; Paschke, Amanda

doi:10.1093/cid/ciz530

Public

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Shared by NobleBlocks on Aug 10, 2019 • 12:00 AM UTC

Authors:

Johann Motsch

Cláudia Murta de Oliveira

Viktor Stus

Abstract

Abstract Background The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections. Methods Randomized, controlled, double-blind, phase 3 trial. Hospitalized ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!